This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamashita, J.-i. Articles by Shin, S. Search for Related Content PubMed PubMed Citation Articles by Yamashita, J.-i. Articles by Shin, S.

Immunoreactive Hepatocyte Growth Factor Is a Strong and Independent Predictor of Recurrence and Survival in Human Breast Cancer¹

Department of Surgery II, Kumamoto University School of Medicine, Honjo 1-1-1, Kumamoto 860 [J-i. Y., M. O., S-i. Y., K. N., M. K., T. S.], and Diagnostic Division, Otsuka Pharmaceutical Co. Ltd., Sendai 224-18, Tokushima 771-01 [S. S.], Japan

Hepatocyte growth factor (HGF) is a stromally derived modulator of epithelial cell proliferation and motility. In the present study, we have measured immunoreactive (ir)-HGF concentration in tumor extracts of 258 primary human breast cancers using an enzyme-linked immunosorbent assay and have evaluated its association with disease-free and overall survival. The median value of ir-HGF concentration was 11.0 ng/100 mg protein (range, 1.4–566.7 ng/100 mg protein). Correlation analyses between ir-HGF concentration and clinicopathological factors showed that the ir-HGF level was correlated only with tumor size (P = 0.05). No significant associations were found between ir-HGF content and age, menopausal status, nodal status, histological type, histological grade, vessel involvement, estrogen receptor, progesterone receptor, type of surgery, or postoperative adjuvant therapy. Breast cancer patients with high ir-HGF concentration had a significantly shorter relapse-free (P = 0.001) and overall survival (P = 0.001) rate when compared to those with low ir-HGF concentration at the cutoff point of 21.7 ng/100 mg protein, which was determined in another group of 82 patients. In multivariate analysis, ir-HGF level was found to be the most important independent factor in predicting relapse-free and overall survival, of greater import than lymph node involvement. The putative role of HGF in breast cancer growth and metastasis is hereby strengthened.

¹ This work was supported by Grant-in-Aid 05151061 for Scientific Research from the Ministry of Education, Science and Culture of Japan.

² To whom correspondence should be addressed: Michio Ogawa, M.D., Department of Surgery II, Kumamoto University School of Medicine, Honjo 1-1-1, Kumamoto 860, Japan.

Received 12/17/93. Accepted 2/21/94.

This article has been cited by other articles:

				D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]

				D. L. Shattuck, J. K. Miller, M. Laederich, M. Funes, H. Petersen, K. L. Carraway III, and C. Sweeney LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy Mol. Cell. Biol., March 1, 2007; 27(5): 1934 - 1946. [Abstract] [Full Text] [PDF]

				D. Generali, S. B. Fox, A. Berruti, J. W. Moore, M. P. Brizzi, N. Patel, G. Allevi, S. Bonardi, S. Aguggini, A. Bersiga, et al. Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer Clin. Cancer Res., January 15, 2007; 13(2): 550 - 558. [Abstract] [Full Text] [PDF]

				T. A. D'Amico, K. R. Brooks, M.-B. M. Joshi, D. Conlon, J. Herndon II, R. P. Petersen, and D. H. Harpole Jr Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection Ann. Thorac. Surg., June 1, 2006; 81(6): 1982 - 1987. [Abstract] [Full Text] [PDF]

				W. G. Jiang, A. Raz, A. Douglas-Jones, and R. E. Mansel Expression of Autocrine Motility Factor (AMF) and Its Receptor, AMFR, in Human Breast Cancer J. Histochem. Cytochem., February 1, 2006; 54(2): 231 - 241. [Abstract] [Full Text] [PDF]

				Y. Ren, B. Cao, S. Law, Y. Xie, P. Y. Lee, L. Cheung, Y. Chen, X. Huang, H. M. Chan, P. Zhao, et al. Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas Clin. Cancer Res., September 1, 2005; 11(17): 6190 - 6197. [Abstract] [Full Text] [PDF]

				H. Khoury, M. A. Naujokas, D. Zuo, V. Sangwan, M. M. Frigault, S. Petkiewicz, D. L. Dankort, W. J. Muller, and M. Park HGF Converts ErbB2/Neu Epithelial Morphogenesis to Cell Invasion Mol. Biol. Cell, February 1, 2005; 16(2): 550 - 561. [Abstract] [Full Text] [PDF]

				C. Parr, G. Watkins, R. E. Mansel, and W. G. Jiang The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer Clin. Cancer Res., January 1, 2004; 10(1): 202 - 211. [Abstract] [Full Text] [PDF]

				X. Wang, P. Le, C. Liang, J. Chan, D. Kiewlich, T. Miller, D. Harris, L. Sun, A. Rice, S. Vasile, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol. Cancer Ther., November 1, 2003; 2(11): 1085 - 1092. [Abstract] [Full Text] [PDF]

				W. G. Jiang, D. Grimshaw, T. A. Martin, G. Davies, C. Parr, G. Watkins, J. Lane, R. Abounader, J. Laterra, and R. E. Mansel Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET Clin. Cancer Res., September 15, 2003; 9(11): 4274 - 4281. [Abstract] [Full Text] [PDF]

				R. V. Hay, B. Cao, R. S. Skinner, L.-M. Wang, Y. Su, J. H. Resau, B. S. Knudsen, M. F. Gustafson, H.-M. Koo, G. F. V. Woude, et al. Radioimmunoscintigraphy of Human Met-Expressing Tumor Xenografts Using Met3, a New Monoclonal Antibody Clin. Cancer Res., September 1, 2003; 9(10): 3839S - 3844. [Abstract] [Full Text] [PDF]

				T. A. Martin, C. Parr, G. Davies, G. Watkins, J. Lane, K. Matsumoto, T. Nakamura, R. E. Mansel, and W. G. Jiang Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist Carcinogenesis, August 1, 2003; 24(8): 1317 - 1323. [Abstract] [Full Text] [PDF]

				M. Wislez, N. Rabbe, J. Marchal, B. Milleron, B. Crestani, C. Mayaud, M. Antoine, P. Soler, and J. Cadranel Hepatocyte Growth Factor Production by Neutrophils Infiltrating Bronchioloalveolar Subtype Pulmonary Adenocarcinoma: Role in Tumor Progression and Death Cancer Res., March 15, 2003; 63(6): 1405 - 1412. [Abstract] [Full Text] [PDF]

				A. Lorenzato, M. Olivero, S. Patane, E. Rosso, A. Oliaro, P. M. Comoglio, and M. F. Di Renzo Novel Somatic Mutations of the MET Oncogene in Human Carcinoma Metastases Activating Cell Motility and Invasion Cancer Res., December 1, 2002; 62(23): 7025 - 7030. [Abstract] [Full Text] [PDF]

				K. A. Walter, M. A. Hossain, C. Luddy, N. Goel, T. E. Reznik, and J. Laterra Scatter Factor/Hepatocyte Growth Factor Stimulation of Glioblastoma Cell Cycle Progression through G1 Is c-Myc Dependent and Independent of p27 Suppression, Cdk2 Activation, or E2F1-Dependent Transcription Mol. Cell. Biol., April 15, 2002; 22(8): 2703 - 2715. [Abstract] [Full Text] [PDF]

				M. Gao, S. Fan, I. D. Goldberg, J. Laterra, R. N. Kitsis, and E. M. Rosen Hepatocyte Growth Factor/Scatter Factor Blocks the Mitochondrial Pathway of Apoptosis Signaling in Breast Cancer Cells J. Biol. Chem., December 7, 2001; 276(50): 47257 - 47265. [Abstract] [Full Text] [PDF]

				W. G. Jiang, D. Grimshaw, J. Lane, T. A. Martin, R. Abounder, J. Laterra, and R. E. Mansel A Hammerhead Ribozyme Suppresses Expression of Hepatocyte Growth Factor/Scatter Factor Receptor c-MET and Reduces Migration and Invasiveness of Breast Cancer Cells Clin. Cancer Res., August 1, 2001; 7(8): 2555 - 2562. [Abstract] [Full Text] [PDF]

				T. Horikawa, T.-S. Sheen, H. Takeshita, H. Sato, M. Furukawa, and T. Yoshizaki Induction of c-Met Proto-Oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the Correlation with Cervical Lymph Node Metastasis of Nasopharyngeal Carcinoma Am. J. Pathol., July 1, 2001; 159(1): 27 - 33. [Abstract] [Full Text] [PDF]

				J. M. Pilewski, T. S. Bumbalo III, A. G. Davis, and J. M. Siegfried Hepatocyte Growth Factor Promotes Tumor Growth in a Novel In Vivo Model of Human Lung Cancer Am. J. Respir. Cell Mol. Biol., May 1, 2001; 24(5): 556 - 562. [Abstract] [Full Text]

				R. Reeves, D. D. Edberg, and Y. Li Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells Mol. Cell. Biol., January 15, 2001; 21(2): 575 - 594. [Abstract] [Full Text]

				V. J. M. Wielenga, R. van der Voort, T. E. I. Taher, L. Smit, E. A. Beuling, C. van Krimpen, M. Spaargaren, and S. T. Pals Expression of c-Met and Heparan-Sulfate Proteoglycan Forms of CD44 in Colorectal Cancer Am. J. Pathol., November 1, 2000; 157(5): 1563 - 1573. [Abstract] [Full Text] [PDF]

				K. Gohji, M. Nomi, Y. Niitani, S. Kitazawa, A. Fujii, Y. Katsuoka, and M. Nakajima Independent Prognostic Value of Serum Hepatocyte Growth Factor in Bladder Cancer J. Clin. Oncol., August 16, 2000; 18(16): 2963 - 2971. [Abstract] [Full Text] [PDF]

				D. C. Bowers, S. Fan, K. A. Walter, R. Abounader, J. A. Williams, E. M. Rosen, and J. Laterra Scatter Factor/Hepatocyte Growth Factor Protects against Cytotoxic Death in Human Glioblastoma via Phosphatidylinositol 3-Kinase- and AKT-dependent Pathways Cancer Res., August 1, 2000; 60(15): 4277 - 4283. [Abstract] [Full Text]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				H. Qiao, R. Saulnier, A. Patryzkat, N. Rahimi, L. Raptis, J. Rossiter, E. Tremblay, and B. Elliott Cooperative Effect of Hepatocyte Growth Factor and Fibronectin in Anchorage-independent Survival of Mammary Carcinoma Cells: Requirement for Phosphatidylinositol 3-Kinase Activity Cell Growth Differ., February 1, 2000; 11(2): 123 - 133. [Abstract] [Full Text]

				S. Ried, C. Jager, M. Jeffers, G. F. Vande Woude, H. Graeff, M. Schmitt, and E. Lengyel Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor J. Biol. Chem., June 4, 1999; 274(23): 16377 - 16386. [Abstract] [Full Text] [PDF]

				D. Ronen, R. T. Altstock, M. Firon, L. Mittelman, T. Sobe, J. H. Resau, G. F. Vande Woude, and I. Tsarfaty Met-HGF/SF Mediates Growth Arrest and Differentiation in T47D Breast Cancer Cells Cell Growth Differ., February 1, 1999; 10(2): 131 - 140. [Abstract] [Full Text]

				N. Rahimi, W. Hung, E. Tremblay, R. Saulnier, and B. Elliott c-Src Kinase Activity Is Required for Hepatocyte Growth Factor-induced Motility and Anchorage-independent Growth of Mammary Carcinoma Cells J. Biol. Chem., December 11, 1998; 273(50): 33714 - 33721. [Abstract] [Full Text] [PDF]

				J. M. Siegfried, L. A. Weissfeld, J. D. Luketich, R. J. Weyant, C. T. Gubish, and R. J. Landreneau The clinical significance of hepatocyte growth factor for non-small cell lung cancer Ann. Thorac. Surg., December 1, 1998; 66(6): 1915 - 1918. [Abstract] [Full Text] [PDF]

				M. Jeffers, M. Fiscella, C. P. Webb, M. Anver, S. Koochekpour, and G. F. Vande Woude The mutationally activated Met receptor mediates motility and metastasis PNAS, November 24, 1998; 95(24): 14417 - 14422. [Abstract] [Full Text] [PDF]

				G. Montrucchio, A. Sapino, B. Bussolati, G. Ghisolfi, S. Rizea-Savu, L. Silvestro, E. Lupia, and G. Camussi Potential Angiogenic Role of Platelet-Activating Factor in Human Breast Cancer Am. J. Pathol., November 1, 1998; 153(5): 1589 - 1596. [Abstract] [Full Text] [PDF]

				M. Lail-Trecker, R. Gulati, and J. J. Peluso A Role for Hepatocyte Growth Factors/Scatter Factor in Regulating Normal and Neoplastic Cells of Reproductive Tissues Reproductive Sciences, May 1, 1998; 5(3): 114 - 121. [Abstract] [PDF]

				A. W. Bell, J.-G. Jiang, Q. Chen, Y. Liu, and R. Zarnegar The Upstream Regulatory Regions of the Hepatocyte Growth Factor Gene Promoter Are Essential for Its Expression in Transgenic Mice J. Biol. Chem., March 20, 1998; 273(12): 6900 - 6908. [Abstract] [Full Text] [PDF]

				J. L. Jakubczak, W. J. Larochelle, and G. Merlino NK1, a Natural Splice Variant of Hepatocyte Growth Factor/Scatter Factor, Is a Partial Agonist In Vivo Mol. Cell. Biol., March 1, 1998; 18(3): 1275 - 1283. [Abstract] [Full Text]

				D Alford, D Baeckstrom, M Geyp, P Pitha, and J Taylor-Papadimitriou Integrin-matrix interactions affect the form of the structures developing from human mammary epithelial cells in collagen or fibrin gels J. Cell Sci., January 2, 1998; 111(4): 521 - 532. [Abstract] [PDF]

				H. Takayama, W. J. LaRochelle, R. Sharp, T. Otsuka, P. Kriebel, M. Anver, S. A. Aaronson, and G. Merlino Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor PNAS, January 21, 1997; 94(2): 701 - 706. [Abstract] [Full Text] [PDF]

				J. Soriano, M. Pepper, T Nakamura, L Orci, and R Montesano Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells J. Cell Sci., January 2, 1995; 108(2): 413 - 430. [Abstract] [PDF]

				W. Hung and B. Elliott Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells J. Biol. Chem., April 6, 2001; 276(15): 12395 - 12403. [Abstract] [Full Text] [PDF]